The Next mRNA Breakthrough May Be in the Packaging

Early NeoVac data hint that redesigned lipid nanoparticles could make mRNA vaccines safer for repeat use

20 Feb 2026

A new chapter in the global race to refine mRNA technology may hinge less on genetic code and more on how it is delivered. Early clinical data from the U.K.-based developer NeoVac indicate that improvements to the microscopic carriers that ferry mRNA into cells could enhance vaccine tolerability and broaden the platform’s reach.

NeoVac recently released preliminary findings from an ongoing Phase I/II study of its experimental vaccine platform, built around a redesigned lipid nanoparticle system. The results, published as a preprint and not yet peer reviewed, focus primarily on early safety and tolerability rather than definitive measures of efficacy.

Lipid nanoparticles, known as LNPs, are fatty molecules that protect fragile strands of messenger RNA and help them enter human cells. They were central to the rapid development of Covid-19 vaccines by companies including BioNTech and Moderna. Since then, researchers have sought to refine these delivery systems to improve consistency and reduce side effects.

In healthy volunteers, NeoVac’s candidate showed improved tolerability compared with first-generation mRNA vaccines, according to the company’s preliminary report and industry coverage. Short-term reactions, such as fever and fatigue, commonly associated with earlier shots, were described as fewer and milder. If confirmed in larger studies, such findings could prove significant for a technology widely praised for speed and effectiveness but sometimes limited by transient side effects.

The longer-term ambition extends beyond single-dose vaccines. Enhanced tolerability is widely considered essential if mRNA platforms are to move into oncology, rare diseases and chronic conditions that may require repeated or sustained dosing. NeoVac has said it is refining how its lipid particles degrade and interact with the immune system, aiming to temper unwanted inflammation while preserving immune activation.

Still, important questions remain. The dataset is limited, longer-term safety and efficacy outcomes are still under evaluation, and scaling new lipid materials for mass production could present manufacturing challenges. Intellectual property disputes over foundational LNP technologies continue to shape the competitive landscape.

Even so, advances in delivery science are emerging as a defining frontier for mRNA research. If next-generation systems can reliably support safer repeat use, the technology could expand well beyond its pandemic-era origins and into broader applications in medicine.